Posts Tagged ‘prescription digital therapeutics’
Pear Therapeutics loses 97% of its market capitalization since 2021, explores strategic alternatives
Pear Therapeutics exploring sale, other ‘strategic alternatives’ (MobiHealth News): Prescription digital therapeutics company Pear Therapeutics is exploring “strategic alternatives,” including a possible company sale, merger or acquisition. In a press release, the company said it hired a financial advisor to look into actions that could “maximize shareholder value.” That includes a potential sale, M&A, divestiture…
Read MorePear Therapeutics raises $175M and goes public via SPAC deal raising the profile of prescription digital therapeutics
Digital health firm Pear goes public, raising $175 million (pharmaforum): Pear will make its debut on the exchange today after combining with Thimble Point – a special purpose acquisition company (SPAC) – in a deal that sidestepped the conventional initial public offering (IPO) route and has propelled its valuation to around $1.6 billion … Pear specialises…
Read MoreIntegrating music, movement and stroke rehabilitation, MedRhythms raises $25M to develop and commercialize digital therapeutic
MedRhythms raises 25m to get patients back in tune after a stroke (TechCrunch): MedRhythms secured $25 million in Series B funding to advance its digital therapy platform aimed at measuring and improving someone’s ability to walk after they have experienced a neurologic injury or disease … Company co-founder and CEO Brian Harris was a neurologic music…
Read MorePrescription software firm Pear Therapeutics to go public via $1.6 billion SPAC deal, harnessing 3 FDA-authorized products and 14 candidates
Pear Therapeutics to Go Public in Roughly $1.6 Billion SPAC Deal (The Wall Street Journal): Medical technology company Pear Therapeutics Inc. has agreed to go public by merging with a blank-check company with ties to the Pritzker Vlock Family Office, betting on the growing role of prescription digital therapeutics. The proposed merger would give the…
Read MoreAkili Interactive Labs raises $160M in equity and debt to transform cognitive healthcare via prescription videogame treatments
Akili raises $110m to build its digital therapeutics pipeline (pharmaforum): EndeavorRx became the first and so far only approved prescription video game treatment in the US when it was cleared by the FDA last year to treat attention-deficit hyperactivity disorder (ADHD), and has also been given a green light in Europe.
Read MoreOhio joins Indiana and Kentucky in funding Pear Therapeutics’ digital addiction treatments
Ohio is third state to fund Pear’s digital therapeutics to tackle addiction (pharmaforum): The company has been pushing for more reimbursement of its three marketed DTx products in the US following a first FDA approval in 2017. Pear said that the Ohio Department of Mental Health and Addiction Services (OhioMHAS) and RecoveryOhio are providing access to…
Read More